Targeting opioid receptors with pharmacological chaperones

Pharmacological Research

Volumn 83, Issue , 2014, Pages 52-62

  Petäjä Repo, Ulla E ^a   Lackman, Jarkko J ^a  

^a UNIVERSITY OF OULU   (Finland)

Author keywords

Endoplasmic reticulum; Opioid receptor; Pharmacological chaperone; Protein folding; Quality control; Up regulation

Indexed keywords

1,2,3,4,4A,5,12,12AALPHA OCTAHYDRO 4AALPHA (3 HYDROXYPHENYL) 2 METHYLQUINOLINO[2,3 G]ISOQUINOLINE; 17 METHYLNALOXONE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; ASIMADOLINE; BREMAZOCINE; BUPRENORPHINE; CHAPERONE; DELTA OPIATE RECEPTOR; DIPRENORPHINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ETHYLKETAZOCINE; ETORPHINE; G PROTEIN COUPLED RECEPTOR; ICI 204 488; KAPPA OPIATE RECEPTOR; LEVOMETHADONE; LEVORPHANOL; MORPHINE; MU OPIATE RECEPTOR; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; NALBUPHINE; NALFURAFINE; NALORPHINE; NALOXONE; NALTREXONE; NALTRIBEN; NALTRINDOLE; NORBINALTORPHIMINE; OPIATE RECEPTOR; OXYMORPHONE; RTI 5989 23; RTI 5989 25; TONAZOCINE; U 50 488 H; UNCLASSIFIED DRUG; UNINDEXED DRUG; LIGAND;

ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; HUMAN; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; UPREGULATION; ANIMAL; CHEMICAL STRUCTURE; DRUG DEVELOPMENT; DRUG EFFECTS; METABOLISM; PROTEIN FOLDING; PROTEIN STABILITY; PROTEIN TRANSPORT;

ANIMALS; DRUG DISCOVERY; ENDOPLASMIC RETICULUM; HUMANS; LIGANDS; MODELS, MOLECULAR; PROTEIN FOLDING; PROTEIN STABILITY; PROTEIN TRANSPORT; RECEPTORS, OPIOID;

EID: 84900504657     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2013.12.001     Document Type: Review

References (110)

1. D.N. Hebert, and M. Molinari In and out of the ER: protein folding, quality control, degradation, and related human diseases Physiol Rev 87 2007 1377 1408 (Pubitemid 350041473)
2. I. Braakman, and N.J. Bulleid Protein folding and modification in the mammalian endoplasmic reticulum Annu Rev Biochem 80 2011 71 99
3. M.H. Smith, H.L. Ploegh, and J.S. Weissman Road to ruin: targeting proteins for degradation in the endoplasmic reticulum Science 334 2011 1086 1090
4. J.L. Brodsky Cleaning up: ER-associated degradation to the rescue Cell 151 2012 1163 1167
5. U. Schubert, L.C. Antón, J. Gibbs, C.C. Norbury, J.W. Yewdell, and J.R. Bennink Rapid degradation of a large fraction of newly synthesized proteins by proteasomes Nature 404 2000 770 774 (Pubitemid 30212405)
6. Y.X. Tao Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications Pharmacol Ther 111 2006 949 973
7. G. Vassart, and S. Costagliola G protein-coupled receptors: mutations and endocrine diseases Nat Rev Endocrinol 7 2011 362 372
8. M. Aridor Visiting the ER: the endoplasmic reticulum as a target for therapeutics in traffic related diseases Adv Drug Deliv Rev 59 2007 759 781 (Pubitemid 47321910)
9. W.E. Balch, R.I. Morimoto, A. Dillin, and J.W. Kelly Adapting proteostasis for disease intervention Science 319 2008 916 919 (Pubitemid 351263754)
10. D.S.T. Ong, and J.W. Kelly Chemical and/or biological therapeutic strategies to ameliorate protein misfolding diseases Curr Opin Cell Biol 23 2011 231 238
11. J.P. Morello, U.E. Petäjä-Repo, D.G. Bichet, and M. Bouvier Pharmacological chaperones: a new twist on receptor folding Trends Pharmacol Sci 21 2000 466 469
12. A. Ulloa-Aguirre, J.A. Janovick, S.P. Brothers, and P.M. Conn Pharmacologic rescue of conformationally defective proteins: implications for the treatment of human disease Traffic 5 2004 821 837 (Pubitemid 39433553)
13. K. Römisch A cure for traffic jams: small molecule chaperones in the endoplasmic reticulum Traffic 5 2004 815 820 (Pubitemid 39433552)
14. V. Bernier, M. Lagacé, D.G. Bichet, and M. Bouvier Pharmacological chaperones: potential treatment for conformational diseases Trends Endocrinol Metab 15 2004 222 228 (Pubitemid 38833993)
15. V. Bernier, M. Lagacé, M.F. Lonergan, M.F. Arthus, D.G. Bichet, and M. Bouvier Functional rescue of the constitutively internalized V2 Vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059 Mol Endocrinol 18 2004 2074 2084 (Pubitemid 39006510)
16. J.P. Morello, A. Salahpour, A. Laperrière, V. Bernier, M.F. Arthus, and M. Lonergan et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants J Clin Invest 105 2000 887 895 (Pubitemid 30203061)
17. U.E. Petäjä-Repo, M. Hogue, S. Bhalla, A. Laperrière, J.P. Morello, and M. Bouvier Ligands act as pharmacological chaperones and increase the efficiency of δ opioid receptor maturation EMBO J 21 2002 1628 1637 (Pubitemid 34614619)
18. J.A. Janovick, G. Maya-Nunez, and P.M. Conn Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target J Clin Endocrinol Metab 87 2002 3255 3262 (Pubitemid 34816374)
19. J. Robert, C. Auzan, M.A. Ventura, and E. Clauser Mechanisms of cell-surface rerouting of an endoplasmic reticulum-retained mutant of the vasopressin V1b/V3 receptor by a pharmacological chaperone J Biol Chem 280 2005 42198 42206 (Pubitemid 43023190)
20. K. Van Craenenbroeck, S.D. Clark, M.J. Cox, J.N. Oak, F. Liu, and H.H.M. Van Tol Folding efficiency is rate-limiting in dopamine D4 receptor biogenesis J Biol Chem 280 2005 19350 19357 (Pubitemid 41379642)
21. 1a receptor J Biol Chem 281 2006 14604 14614 (Pubitemid 43855164)
22. Y. Chen, C. Chen, Y. Wang, and L.Y. Liu-Chen Ligands regulate cell surface level of the human κ opioid receptor by activation-induced down-regulation and pharmacological chaperone-mediated enhancement: differential effects of nonpeptide and peptide agonists J Pharmacol Exp Ther 319 2006 765 775
23. J.A. Janovick, P.E. Knollman, S.P. Brothers, R. Ayala-Yáñez, A.S. Aziz, and P.M. Conn Regulation of G protein-coupled receptor trafficking by inefficient plasma membrane expression: molecular basis of an evolved strategy J Biol Chem 281 2006 8417 8425 (Pubitemid 43847943)
24. K.M. Wannemacher, P.N. Yadav, and R.D. Howells A select set of opioid ligands induce up-regulation by promoting the maturation and stability of the rat κ-opioid receptor in human embryonic kidney 293 cells J Pharmacol Exp Ther 323 2007 614 625 (Pubitemid 350005136)
25. T.T. Leskelä, P.M.H. Markkanen, I.A. Alahuhta, J.T. Tuusa, and U.E. Petäjä-Repo Phe27Cys polymorphism alters the maturation and subcellular localization of the human δ opioid receptor Traffic 10 2009 116 129
26. R. Fredriksson, M.C. Lagerström, L.G. Lundin, and H.B. Schiöth The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints Mol Pharmacol 63 2003 1256 1272 (Pubitemid 36627220)
27. P.Y. Law, Y.H. Wong, and H.H. Loh Molecular mechanisms and regulation of opioid receptor signaling Annu Rev Pharmacol Toxicol 40 2000 389 430 (Pubitemid 30340688)
28. M. Waldhoer, S.E. Bartlett, and J.L. Whistler Opioid receptors Annu Rev Biochem 73 2004 953 990 (Pubitemid 39050391)
29. B.L. Kieffer, and C.J. Evans Opioid receptors: from binding sites to visible molecules in vivo Neuropharmacology 56 Suppl. 1 2009 205 212
30. Y. Feng, X. He, Y. Yang, D. Chao, L.H. Lazarus, and Y. Xia Current research on opioid receptor function Curr Drug Targets 13 2012 230 246
31. R.J. Bodnar Endogenous opiates and behavior: 2012 Peptides 50 2013 55 95
32. B.M. Cox Recent developments in the study of opioid receptors Mol Pharmacol 83 2013 723 728
33. C. Mollereau, M. Parmentier, P. Mailleux, J.L. Butour, C. Moisand, and P. Chalon et al. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization FEBS Lett 341 1994 33 38
34. J.C. Meunier, C. Mollereau, L. Toll, C. Suaudeau, C. Moisand, and P. Alvinerie et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor Nature 377 1995 532 535
35. S. Granier, A. Manglik, A.C. Kruse, T.S. Kobilka, F.S. Thian, and W.I. Weis et al. Structure of the δ-opioid receptor bound to naltrindole Nature 485 2012 400 404
36. A. Manglik, A.C. Kruse, T.S. Kobilka, F.S. Thian, J.M. Mathiesen, and R.K. Sunahara et al. Crystal structure of the μ-opioid receptor bound to a morphinan antagonist Nature 485 2012 321 326
37. A.A. Thompson, W. Liu, E. Chun, V. Katritch, H. Wu, and E. Vardy et al. Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic Nature 485 2012 395 399
38. H. Wu, D. Wacker, M. Mileni, V. Katritch, G.W. Han, and E. Vardy et al. Structure of the human κ-opioid receptor in complex with JDTic Nature 485 2012 327 332
39. R. Rozenfeld, and L.A. Devi Receptor heteromerization and drug discovery Trends Pharmacol Sci 31 2010 124 130
40. R.M. van Rijn, J.L. Whistler, and M. Waldhoer Opioid-receptor-heteromer- specific trafficking and pharmacology Curr Opin Pharmacol 10 2010 73 79
41. C.M. Costantino, I. Gomes, S.D.J. Stockton, M.P. Lim, and L.A. Devi Opioid receptor heteromers in analgesia Expert Rev Mol Med 14 2012 e9
42. K. Ikeda, S. Ide, W. Han, M. Hayashida, G.R. Uhl, and I. Sora How individual sensitivity to opiates can be predicted by gene analyses Trends Pharmacol Sci 26 2005 311 317 (Pubitemid 40733524)
43. P. Mayer, and V. Höllt Pharmacogenetics of opioid receptors and addiction Pharmacogenet Genomics 16 2006 1 7 (Pubitemid 41803871)
44. A.A. Somogyi, D.T. Barratt, and J.K. Coller Pharmacogenetics of opioids Clin Pharmacol Ther 81 2007 429 444 (Pubitemid 46364493)
45. J.Y. Khokhar, C.S. Ferguson, A.Z.X. Zhu, and R.F. Tyndale Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment Annu Rev Pharmacol Toxicol 50 2010 39 61
46. T.K. Clarke, R.C. Crist, A. Ang, L.M. Ambrose-Lanci, F.W. Lohoff, and A.J. Saxon et al. Genetic variation in OPRD1 and the response to treatment for opioid dependence with buprenorphine in European-American females Pharmacogenomics J October 2013 10.1038/tpj.2013.30 [Epub ahead of print]
47. J. Kazius, K. Wurdinger, M. van Iterson, J. Kok, T. Bäck, and A.P. Ijzerman GPCR NaVa database: natural variants in human G protein-coupled receptors Hum Mutat 29 2008 39 44
48. J. Gelernter, and H.R. Kranzler Variant detection at the δ opioid receptor (OPRD1) locus and population genetics of a novel variant affecting protein sequence Hum Genet 107 2000 86 88 (Pubitemid 30598953)
49. C. Bond, K.S. LaForge, M. Tian, D. Melia, S. Zhang, and L. Borg et al. Single-nucleotide polymorphism in the human mu opioid receptor gene alters β-endorphin binding and activity: possible implications for opiate addiction Proc Natl Acad Sci U S A 95 1998 9608 9613 (Pubitemid 28506279)
50. T. Kroslak, K.S. LaForge, R.J. Gianotti, A. Ho, D.A. Nielsen, and M.J. Kreek The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor J Neurochem 103 2007 77 87 (Pubitemid 47404205)
51. P. Huang, C. Chen, S.D. Mague, J.A. Blendy, and L.Y. Liu-Chen A common single nucleotide polymorphism A118G of the μ opioid receptor alters its N-glycosylation and protein stability Biochem J 441 2012 379 386
52. U.E. Petäjä-Repo, M. Hogue, A. Laperrière, P. Walker, and M. Bouvier Export from the endoplasmic reticulum represents the limiting step in the maturation and cell surface expression of the human δ opioid receptor J Biol Chem 275 2000 13727 13736 (Pubitemid 30257444)
53. U.E. Petäjä-Repo, M. Hogue, A. Laperrière, S. Bhalla, P. Walker, and M. Bouvier Newly synthesized human δ opioid receptors retained in the endoplasmic reticulum are retrotranslocated to the cytosol, deglycosylated, ubiquitinated, and degraded by the proteasome J Biol Chem 276 2001 4416 4423
54. T.T. Leskelä, J.J. Lackman, M.M. Vierimaa, H. Kobayashi, M. Bouvier, and U.E. Petäjä-Repo Cys27 variant of the human δ opioid receptor modulates maturation and cell surface delivery of Phe27 variant via heteromerization J Biol Chem 287 2012 5008 5020
55. V. Chaipatikul, L.J. Erickson-Herbrandson, H.H. Loh, and P.Y. Law Rescuing the traffic-deficient mutants of rat μ-opioid receptors with hydrophobic ligands Mol Pharmacol 64 2003 32 41 (Pubitemid 36759815)
56. J.P. Fortin, L. Ci, J. Schroeder, C. Goldstein, M.C. Montefusco, and I. Peter et al. The μ-opioid receptor variant N190K is unresponsive to peptide agonists yet can be rescued by small-molecule drugs Mol Pharmacol 78 2010 837 845
57. J. Barg, R. Levy, and R. Simantov Up-regulation of opiate receptors by opiate antagonists in neuroblastoma-glioma cell culture: the possibility of interaction with guanosine triphosphate-binding proteins Neurosci Lett 50 1984 133 137 (Pubitemid 14074938)
58. J.E. Zadina, S.L. Chang, L.J. Ge, and A.J. Kastin Mu opiate receptor down-regulation by morphine and up-regulation by naloxone in SH-SY5Y human neuroblastoma cells J Pharmacol Exp Ther 265 1993 254 262 (Pubitemid 23320968)
59. J.E. Zadina, L.M. Harrison, L.J. Ge, A.J. Kastin, and S.L. Chang Differential regulation of mu and delta opiate receptors by morphine, selective agonists and antagonists and differentiating agents in SH-SY5Y human neuroblastoma cells J Pharmacol Exp Ther 270 1994 1086 1096
60. T.T. Leskelä, P.M.H. Markkanen, E.M. Pietilä, J.T. Tuusa, and U.E. Petäjä-Repo Opioid receptor pharmacological chaperones act by binding and stabilizing newly synthesized receptors in the endoplasmic reticulum J Biol Chem 282 2007 23171 23183 (Pubitemid 47311942)
61. J. Li, C. Chen, P. Huang, and L.Y. Liu-Chen Inverse agonist up-regulates the constitutively active D3. 49(164)Q mutant of the rat μ-opioid receptor by stabilizing the structure and blocking constitutive internalization and down-regulation Mol Pharmacol 60 2001 1064 1075 (Pubitemid 33027442)
62. S. Wüller, B. Wiesner, A. Löffler, J. Furkert, G. Krause, and R. Hermosilla et al. Pharmacochaperones post-translationally enhance cell surface expression by increasing conformational stability of wild-type and mutant vasopressin V2 receptors J Biol Chem 279 2004 47254 47263 (Pubitemid 39518382)
63. 1-adrenergic receptor N-terminal cleavage and stabilization in vivo and in vitro Mol Pharmacol 83 2013 1 13
64. C.M. Tan, H.H. Nickols, and L.E. Limbird Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation J Biol Chem 278 2003 35678 35686 (Pubitemid 37102342)
65. U. Gether, J.A. Ballesteros, R. Seifert, E. Sanders-Bush, H. Weinstein, and B.K. Kobilka Structural instability of a constitutively active G protein-coupled receptor. Agonist-independent activation due to conformational flexibility J Biol Chem 272 1997 2587 2590 (Pubitemid 27053295)
66. 2- adrenergic receptor: pharmacological creation of a phenotype in transgenic mice Proc Natl Acad Sci U S A 94 1997 137 141
67. 2 receptor Mol Pharmacol 57 2000 890 898 (Pubitemid 30253371)
68. 2a- adrenergic receptor conformational stability and cell-surface turnover Mol Pharmacol 59 2001 929 938 (Pubitemid 32279611)
69. J. Li, P. Huang, C. Chen, J.K. de Riel, H. Weinstein, and L.Y. Liu-Chen Constitutive activation of the μ opioid receptor by mutation of D3.49(164), but not D3.32(147): D3.49(164) is critical for stabilization of the inactive form of the receptor and for its expression Biochemistry 40 2001 12039 12050 (Pubitemid 32946545)
70. T.W. Kahn, J.M. Sturtevant, and D.M. Engelman Thermodynamic measurements of the contributions of helix-connecting loops and of retinal to the stability of bacteriorhodopsin Biochemistry 31 1992 8829 8839
71. 1 ATP synthase Eur J Biochem 244 1997 441 448 (Pubitemid 27110746)
72. M.S. Celej, G.G. Montich, and G.D. Fidelio Protein stability induced by ligand binding correlates with changes in protein flexibility Protein Sci 12 2003 1496 1506 (Pubitemid 36759353)
73. M. Filizola, and L.A. Devi Grand opening of structure-guided design for novel opioids Trends Pharmacol Sci 34 2012 6 12
74. J.A. Janovick, M. Goulet, E. Bush, J. Greer, D.G. Wettlaufer, and P.M. Conn Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor J Pharmacol Exp Ther 305 2003 608 614 (Pubitemid 36459177)
75. N. Asano, S. Ishii, H. Kizu, K. Ikeda, K. Yasuda, and A. Kato et al. In vitro inhibition and intracellular enhancement of lysosomal α- galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives Eur J Biochem 267 2000 4179 4186 (Pubitemid 30436114)
76. E. Ficker, C.A. Obejero-Paz, S. Zhao, and A.M. Brown The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-gogo-related gene (HERG) mutations J Biol Chem 277 2002 4989 4998 (Pubitemid 34968538)
77. A. Helenius, and M. Aebi Roles of N-linked glycans in the endoplasmic reticulum Annu Rev Biochem 73 2004 1019 1049 (Pubitemid 39050393)
78. M. Aebi, R. Bernasconi, S. Clerc, and M. Molinari N-glycan structures: recognition and processing in the ER Trends Biochem Sci 35 2010 74 82
79. T.G. Rozell, D.P. Davis, Y. Chai, and D.L. Segaloff Association of gonadotropin receptor precursors with the protein folding chaperone calnexin Endocrinology 139 1998 1588 1593 (Pubitemid 28513813)
80. J.P. Morello, A. Salahpour, U.E. Petäjä-Repo, A. Laperrière, M. Lonergan, and M.F. Arthus et al. Association of calnexin with wild type and mutant AVPR2 that causes nephrogenic diabetes insipidus Biochemistry 40 2001 6766 6775 (Pubitemid 32538222)
81. M. Lu, F. Echeverri, and B.D. Moyer Endoplasmic reticulum retention, degradation, and aggregation of olfactory G-protein coupled receptors Traffic 4 2003 416 433 (Pubitemid 36656489)
82. 1 receptor Biochem Biophys Res Commun 340 2006 395 402 (Pubitemid 43021761)
83. P.M.H. Markkanen, and U.E. Petäjä-Repo N-glycan-mediated quality control in the endoplasmic reticulum is required for the expression of correctly folded δ-opioid receptors at the cell surface J Biol Chem 283 2008 29086 29098
84. X. Ge, H.H. Loh, and P.Y. Law μ-Opioid receptor cell surface expression is regulated by its direct interaction with Ribophorin I Mol Pharmacol 75 2009 1307 1316
85. S.M. Noorwez, R.R.K. Sama, and S. Kaushal Calnexin improves the folding efficiency of mutant rhodopsin in the presence of pharmacological chaperone 11-cis-retinal J Biol Chem 284 2009 33333 33342
86. R.W. Doms, G. Russ, and J.W. Yewdell Brefeldin A redistributes resident and itinerant Golgi proteins to the endoplasmic reticulum J Cell Biol 109 1989 61 72 (Pubitemid 19180119)
87. R.S. Saliba, P.M.G. Munro, P.J. Luthert, and M.E. Cheetham The cellular fate of mutant rhodopsin: quality control, degradation and aggresome formation J Cell Sci 115 2002 2907 2918
88. L.B. Cook, C.C. Zhu, and P.M. Hinkle Thyrotropin-releasing hormone receptor processing: role of ubiquitination and proteasomal degradation Mol Endocrinol 17 2003 1777 1791 (Pubitemid 37072294)
89. Y. Huang, J. Niwa, G. Sobue, and G.E. Breitwieser Calcium-sensing receptor ubiquitination and degradation mediated by the E3 ubiquitin ligase dorfin J Biol Chem 281 2006 11610 11617 (Pubitemid 43855418)
90. I. Schwieger, K. Lautz, E. Krause, W. Rosenthal, B. Wiesner, and R. Hermosilla Derlin-1 and p97/valosin-containing protein mediate the endoplasmic reticulum-associated degradation of human V2 vasopressin receptors Mol Pharmacol 73 2008 697 708 (Pubitemid 351397875)
91. K. Zemoura, M. Schenkel, M.A. Acuna, G.E. Yevenes, H.U. Zeilhofer, and D. Benke Endoplasmic reticulum associated degradation (ERAD) controls cell surface expression of GABAB receptors J Biol Chem 288 2013 34897 34905
92. 3H-naloxone in the mouse brain: effect of ions and tolerance development Life Sci 14 1974 2393 2404
93. A. Tempel, E.L. Gardner, and R.S. Zukin Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation J Pharmacol Exp Ther 232 1985 439 444 (Pubitemid 15162904)
94. B.J. Morris, M.J. Millan, and A. Herz Antagonist-induced opioid receptor up-regulation. II. Regionally specific modulation of mu, delta and kappa binding sites in rat brain revealed by quantitative autoradiography J Pharmacol Exp Ther 247 1988 729 736
95. B.C. Yoburn, M.C. Luke, G.W. Pasternak, and C.E. Inturrisi Upregulation of opioid receptor subtypes correlates with potency changes of morphine and DADLE Life Sci 43 1988 1319 1324
96. M.M. Belcheva, J. Barg, R.J. McHale, S. Dawn, M.T. Ho, and E. Ignatova et al. Differential down- and up-regulation of rat brain opioid receptor types and subtypes by buprenorphine Mol Pharmacol 44 1993 173 179 (Pubitemid 23230474)
97. B. Kest, C.E. Lee, S. Jenab, B. Kao, and C.E. Inturrisi Chronic naltrexone differentially affects supraspinal δ-opioid receptor-mediated antinociception Eur J Pharmacol 345 1998 47 53 (Pubitemid 28179469)
98. E.M. Unterwald, B. Anton, T. To, H. Lam, and C.J. Evans Quantitative immunolocalization of mu opioid receptors: regulation by naltrexone Neuroscience 85 1998 897 905 (Pubitemid 28223650)
99. H.M. Lesscher, A. Bailey, J.P.H. Burbach, J.M. Van Ree, I. Kitchen, and M.A.F.M. Gerrits Receptor-selective changes in μ-, δ- and κ-opioid receptors after chronic naltrexone treatment in mice Eur J Neurosci 17 2003 1006 1012 (Pubitemid 36411597)
100. S. Sirohi, P. Kumar, and B.C. Yoburn μ-opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacy J Pharmacol Exp Ther 323 2007 701 707 (Pubitemid 350005140)
101. P.M. Conn, P.E. Knollman, S.P. Brothers, and J.A. Janovick Protein folding as posttranslational regulation: evolution of a mechanism for controlled plasma membrane expression of a G protein-coupled receptor Mol Endocrinol 20 2006 3035 3041 (Pubitemid 44833553)
102. S. Jenab, B. Kest, and C.E. Inturrisi Assessment of delta opioid antinociception and receptor mRNA levels in mouse after chronic naltrexone treatment Brain Res 691 1995 69 75
103. E.M. Unterwald, J.M. Rubenfeld, Y. Imai, J.B. Wang, G.R. Uhl, and M.J. Kreek Chronic opioid antagonist administration upregulates mu opioid receptor binding without altering mu opioid receptor mRNA levels Brain Res Mol Brain Res 33 1995 351 355
104. M.P. Castelli, M. Melis, M. Mameli, P. Fadda, G. Diaz, and G.L. Gessa Chronic morphine and naltrexone fail to modify mu-opioid receptor mRNA levels in the rat brain Brain Res Mol Brain Res 45 1997 149 153 (Pubitemid 27182237)
105. C. Hiller, J. Kühhorn, and P. Gmeiner Class A G-protein-coupled receptor (GPCR) dimers and bivalent ligands J Med Chem 56 2013 6542 6559
106. D. Wang, X. Sun, L.M. Bohn, and W. Sadée Opioid receptor homo- and heterodimerization in living cells by quantitative bioluminescence resonance energy transfer Mol Pharmacol 67 2005 2173 2184 (Pubitemid 41007796)
107. A. Hasbi, T. Nguyen, T. Fan, R. Cheng, A. Rashid, and M. Alijaniaram et al. Trafficking of preassembled opioid μ-δ heterooligomer-Gz signaling complexes to the plasma membrane: coregulation by agonists Biochemistry 46 2007 12997 13009 (Pubitemid 350086219)
108. K. Brillet, B.L. Kieffer, and D. Massotte Enhanced spontaneous activity of the mu opioid receptor by cysteine mutations: characterization of a tool for inverse agonist screening BMC Pharmacol 3 2003 14
109. P.A. Zaki, D.E. Keith Jr., G.A. Brine, F.I. Carroll, and C.J. Evans Ligand-induced changes in surface μ-opioid receptor number: relationship to G protein activation J Pharmacol Exp Ther 292 2000 1127 1134 (Pubitemid 30136610)
110. P.A. Zaki, D.E. Keith Jr., J.B. Thomas, F.I. Carroll, and C.J. Evans Agonist-, antagonist-, and inverse agonist-regulated trafficking of the δ-opioid receptor correlates with, but does not require, G protein activation J Pharmacol Exp Ther 298 2001 1015 1020 (Pubitemid 32761917)